Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Forty eight out of 53 (91%) patients had 25(OH)D levels < 30 ng/ml (p < 0.001).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D and Disease Severity in Multiple Sclerosis: Baseline Data From the Randomized Controlled Trial (EVIDIMS)

Source: Article title.

To account for sunlight intensity as a possible confounder, patients were recruited from a single geographic region in the north-eastern part of Germany.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D and Disease Severity in Multiple Sclerosis: Baseline Data From the Randomized Controlled Trial (EVIDIMS)

Randomised controlled trial · Frontiers in Neurology · 2020

Original publication title

Vitamin D and Disease Severity in Multiple Sclerosis: Baseline Data From the Randomized Controlled Trial (EVIDIMS)

Priscilla Bäcker-Koduah; Judith Bellmann-Strobl; Michael Scheel; Jens Wuerfel; Klaus-Dieter Wernecke; Jan Dörr; Alexander Ulrich Brandt; Friedemann Paul

Copyright © 2020 Bäcker-Koduah, Bellmann-Strobl, Scheel, Wuerfel, Wernecke, Dörr, Brandt and Paul.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Interpretation:

Most patients recruited in the EVIDIMS study were vitamin D deficient. Higher 25(OH)D levels were associated with reduced T2 weighted lesion count and lower EDSS scores.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To investigate the associations between hypovitaminosis D and disease activity in a cohort of relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) patients.

Source: Objective:

Abstract: What methods does the paper describe?

In 51 RRMS and 2 CIS patients on stable interferon-β-1b (IFN-β-1b) treatment recruited to the EVIDIMS study (Efficacy of Vitamin D Supplementation in Multiple Sclerosis (NCT01440062) baseline serum vitamin D levels were evaluated. Patients were dichotomized based on the definition of vitamin D deficiency which is reflected by a < 30 vs. ≥ 30 ng/ml level of 25-hydroxyvitamin D (25(OH)D). Possible associations between vitamin D deficiency and both clinical and MRI features of the disease were analyzed.

Source: Methods:

Abstract: Results

Median (25, 75% quartiles, Q) 25(OH)D level was 18 ng/ml (12, 24). Forty eight out of 53 (91%) patients had 25(OH)D levels < 30 ng/ml (p < 0.001). Patients with 25(OH)D ≥ 30 ng/ml had lower median (25, 75% Q) T2-weighted lesion counts [25 (24, 33)] compared to patients with 25(OH)D < 30 ng/ml [60 (36, 84), p = 0.03; adjusted for age, gender and disease duration: p < 0.001]. Expanded disability status scale (EDSS) score was negatively associated with serum 25(OH)D levels in a multiple linear regression, including age, sex, and disease duration (adjusted: p < 0.001).

Source: Results:

Abstract: Interpretation

Most patients recruited in the EVIDIMS study were vitamin D deficient. Higher 25(OH)D levels were associated with reduced T2 weighted lesion count and lower EDSS scores.

Source: Interpretation:
Authors’ abstract

Objective:

To investigate the associations between hypovitaminosis D and disease activity in a cohort of relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) patients.

Methods:

In 51 RRMS and 2 CIS patients on stable interferon-β-1b (IFN-β-1b) treatment recruited to the EVIDIMS study (Efficacy of Vitamin D Supplementation in Multiple Sclerosis (NCT01440062) baseline serum vitamin D levels were evaluated. Patients were dichotomized based on the definition of vitamin D deficiency which is reflected by a < 30 vs. ≥ 30 ng/ml level of 25-hydroxyvitamin D (25(OH)D). Possible associations between vitamin D deficiency and both clinical and MRI features of the disease were analyzed.

Results:

Median (25, 75% quartiles, Q) 25(OH)D level was 18 ng/ml (12, 24). Forty eight out of 53 (91%) patients had 25(OH)D levels < 30 ng/ml (p < 0.001). Patients with 25(OH)D ≥ 30 ng/ml had lower median (25, 75% Q) T2-weighted lesion counts [25 (24, 33)] compared to patients with 25(OH)D < 30 ng/ml [60 (36, 84), p = 0.03; adjusted for age, gender and disease duration: p < 0.001]. Expanded disability status scale (EDSS) score was negatively associated with serum 25(OH)D levels in a multiple linear regression, including age, sex, and disease duration (adjusted: p < 0.001).

Interpretation:

Most patients recruited in the EVIDIMS study were vitamin D deficient. Higher 25(OH)D levels were associated with reduced T2 weighted lesion count and lower EDSS scores.

Publication and source details

Original title: Vitamin D and Disease Severity in Multiple Sclerosis: Baseline Data From the Randomized Controlled Trial (EVIDIMS)

Priscilla Bäcker-Koduah; Judith Bellmann-Strobl; Michael Scheel; Jens Wuerfel; Klaus-Dieter Wernecke; Jan Dörr; Alexander Ulrich Brandt; Friedemann Paul

Frontiers in Neurology · 2020

Edited by: Valentina Tomassini, Cardiff University, United Kingdom

Reviewed by: Emanuele D'Amico, University of Catania, Italy; Tatsuro Misu, Tohoku University, Japan

*Correspondence: Friedemann Paul friedemann.paul@charite.de

This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology

†These authors share last authorship

Copyright © 2020 Bäcker-Koduah, Bellmann-Strobl, Scheel, Wuerfel, Wernecke, Dörr, Brandt and Paul.2020Bäcker-Koduah, Bellmann-Strobl, Scheel, Wuerfel, Wernecke, Dörr, Brandt and Paulhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T13:19:45.811094+00:00

DOI: 10.3389/fneur.2020.00129 · PMC7052055